Business

First Round of Adalimumab Biosimilar Launches in July

July 2nd 2023

By Skylar Jeremias

After years of waiting and legal battles, the first of the 8 adalimumab biosimilars expected to launch in July 2023 have entered the market.

Biosimilars Business Roundup: June 2023

July 1st 2023

By Skylar Jeremias

Article

As the US biosimilar industry prepares for a busy summer, businesses worldwide make strides to elevate their biosimilars portfolio, from some business extending and strengthening their partnerships to new deals for adalimumab products ahead of US launches.

Payers Reveal Most Significant Factors Impacting Biosimilar Coverage Decisions

June 29th 2023

By Justina Petrullo

Article

It was found that cancer treatment, pediatric population, and coverage restriction of reference products were revealed as some of the strongest factors associated with biosimilar coverage decisions by US commercial health plans relative to reference products.

The Age of Adalimumab Is Upon Us: How Stakeholders Can Prepare

June 28th 2023

By Skylar Jeremias

Article

The Center for Biosimilars® provides an updated look on the adalimumab biosimilars that are coming down the US pipeline as well as what stakeholders need to know and how they can prepare ahead of the US launch of 8 adalimumab biosimilars in July 2023.

Sandoz Roadmap Aims to Increase Worldwide Biosimilar Adoption by 2030

June 27th 2023

By Laura Joszt, MA

Article

The Act4Biosimilars Action Plan seeks to increase biosimilar adoption by at least 30 percentage points in 30-plus countries by 2030.

Roundup: Coherus Resolves AbbVie Dispute; Bio-Thera Solutions and Celltrion Expand Respective Partnerships

June 17th 2023

By Skylar Jeremias

Article

Coherus Biosciences and AbbVie agree to resolve a dispute regarding Coherus’ partnership with the Mark Cuban Cost Plus Drug Company and an adalimumab biosimilar, and Celltrion and Bio-Thera Solutions expand their respective partnerships to include more biosimilar products.

Eye on Pharma: First PBM to Cover Yusimry; Celltrion to Test Ocrevus Biosimilar; Another Stelara Settlement

June 15th 2023

By Skylar Jeremias

Article

SmithRx becomes the first pharmacy benefit manager (PBM) to announce it will cover Yusimry, 1 of 9 FDA-approved adalimumab biosimilars; Celltrion Healthcare receives a thumbs-up from the FDA to test a biosimilar for Ocrevus; Alvotech and Teva Pharmaceuticals settle with Johnson & Johnson over their biosimilar referencing Stelara.

Medicare 340B Program May Be Reducing Biosimilar Uptake

June 8th 2023

By Laura Joszt, MA

Article

New research has found the 340B program is slowing uptake of biosimilars by incentivizing use of more expensive biologics.

Dr Fran Gregory Discusses the Future Landscape of the Biosimilars Marketplace

June 7th 2023

By Pearl Steinzor

Video

Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses what the future biosimilars marketplace may look like compared with generics and reference products at Asembia 2023.

Spain Could Save Millions With Greater Bevacizumab Biosimilar Adoption

June 5th 2023

By Justina Petrullo

Article

If biosimilars are introduced to Spain, they will most likely save money in the pharmacological budget, according to a budget impact analysis model.